Temozolomide: Mechanisms of action, repair and resistance

Current Molecular Pharmacology

Volumn 5, Issue 1, 2012, Pages 102-114

  Zhang, Jihong ^a   Stevens, Malcolm F G ^b   Bradshaw, Tracey D ^b  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Base excision repair; Glioblastoma multiforme; Methyltransferase; Mismatch repair; O6 methylguanine methylguanine; Temozolomide

Indexed keywords

6 O METHYLGUANINE; ANTINEOPLASTIC AGENT; AP ENDONUCLEASE 1; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; GLUTATHIONE TRANSFERASE P1; IMIDAZOTETRAZINE; LOMEGUATRIB; LUCANTHRONE; METHOXYAMINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MSH2; PROTEIN MSH3; PROTEIN MSH6; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VELIPARIB;

ADVANCED CANCER; ADVANCED SOLID TUMOR; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE ARREST; CPG ISLAND; DNA ALKYLATION; DNA DAMAGE; DNA METHYLATION; DNA REPLICATION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG RESPONSE; EXCISION REPAIR; GENE INACTIVATION; GENE SILENCING; GLIOBLASTOMA; HUMAN; MELANOMA; METASTASIS; METASTATIC MELANOMA; MISMATCH REPAIR; NONHUMAN; PH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMBINATION REPAIR; SOLID TUMOR; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; DACARBAZINE; DNA GLYCOSYLASES; DNA MODIFICATION METHYLASES; DNA REPAIR; DNA REPAIR ENZYMES; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; GUANINE; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84862925785     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205010102     Document Type: Article

References (126)

1. Laperriere, N.; Zuraw, L.; Cairncross, G.; Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother. Oncol., 2002, 64(3), 259-273.
2. Huse, J.T.; Holland, E.C. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer, 2010, 10(5), 319-331.
3. Furnari, F.B.; Fenton, T.; Bachoo, R.M.; Mukasa, A.; Stommel, J.M.; Stegh, A.; Hahn, W.C.; Ligon, K.L.; Louis, D.N.; Brennan, C.; Chin, L.; DePinho, R.A.; Cavenee, W.K. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev., 2007, 21(21), 2683-2710.
4. Stupp, R.; Hegi, M.E.; Mason, W.P.; van den Bent, M.J.; Taphoorn, M.J.B.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.; Belanger, K.; Hau, P.; Brandes, A.A.; Gijtenbeek, J.; Marosi, C.; Vecht, C.J.; Mokhtari, K.; Wesseling, P.; Villa, S.; Eisenhauer, E.; Gorlia, T.; Weller, M.; Lacombe, D.; Cairncross, J.G.; Mirimanoff, R.O.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol., 2009, 10(5), 459-466.
5. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.G.; Eisenhauer, E.; Mirimanoff, R.O.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352(10), 987-996.
6. Newlands, E.S.; Blackledge, G.R.; Slack, J.A.; Rustin, G.J.; Smith, D.B.; Stuart, N.S.; Quarterman, C.P.; Hoffman, R.; Stevens, M.F.; Brampton, M.H. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer, 1992, 65(2), 287-291.
7. Tsang, L.L.; Farmer, P.B.; Gescher, A.; Slack, J.A. Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother. Pharmacol., 1990, 26(6), 429-436.
8. Denny, B.J.; Wheelhouse, R.T.; Stevens, M.F.; Tsang, L.L.; Slack, J.A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry, 1994, 33, 9045-9051.
9. Tisdale, M.J. Antitumor imidazotetrazines-XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem. Pharmacol., 1987, 36(4), 457-462.
10. Rottenberg, D.A.; Ginos, J.Z.; Kearfott, K.J.; Junck, L.; Bigner, D.D. In vivo measurement of regional brain tissue pH using positron emission tomography. Ann. Neurol., 1984, (Suppl. 15), S98-102.
11. Drabløs, F.; Feyzi, E.; Aas, P.A.; Vaagbø, C.B.; Kavli, B.; Bratlie, M.S.; Peña-Diaz, J.; Otterlei, M.; Slupphaug, G.; Krokan, H.E. Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair, 2004, 3(11), 1389-1407.
12. Wedge, S.R.; Porteous, J.K.; Newlands, E.S. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br. J. Cancer, 1996, 74(7), 1030-1036.
13. Wedge, S.R.; Newlands, E.S. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br. J. Cancer, 1996, 73(9), 1049-1052.
14. Wedge, S.R.; Porteus, J.K.; May, B.L.; Newlands, E.S. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Br. J. Cancer, 1996, 73(4), 482-490.
15. Kyrtopoulos, S.A.; Anderson, L.M.; Chhabra, S.K.; Souliotis, V.L.; Pletsa, V.; Valavanis, C.; Georgiadis, P. DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance. Cancer Detect. Prev., 1997, 21(5), 391-405.
16. Margison, G.P.; Santibanez-Koref, M.F. O-6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays, 2002, 24(3), 255-266.
17. Mojas, N.; Lopes, M.; Jiricny, J. Mismatch repair-dependent processing of methylation damage gives rise to persistent singlestranded gaps in newly replicated DNA. Genes Dev., 2007, 21(24), 3342-3355.
18. Cejka, P.; Stojic, L.; Mojas, N.; Russell, A.M.; Heinimann, K.; Cannavo, E.; di Pietro, M.; Marra, G.; Jiricny, J. Methylationinduced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO J., 2003, 22(9), 2245-2254.
19. Roos, W.; Baumgartner, M.; Kaina, B. Apoptosis triggered by DNA damage O-6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene, 2004, 23(2), 359-367.
20. Zhukovskaya, N.; Branch, P.; Aquilina, G.; Karran, P. DNA replication arrest and tolerance to DNA methylation damage. Carcinogenesis, 1994, 15(10), 2189-2194.
21. Stojic, L.; Brun, R.; Jiricny, J. Mismatch repair and DNA damage signalling. DNA Repair (Amst), 2004, 3(8-9), 1091-1101.
22. D'Atri, S.; Tentori, L.; Lacal, P.M.; Graziani, G.; Pagani, E.; Benincasa, E.; Zambruno, G.; Bonmassar, E.; Jiricny, J. Involvement of the mismatch repair system in temozolomideinduced apoptosis. Mol. Pharmacol., 1998, 54(2), 334-341.
23. Horton, J.K.; Wilson, S.H. Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency. DNA Repair, 2007, 6(4), 530-543.
24. Lim, A.; Li, B.F. The nuclear targeting and nuclear retention properties of a human DNA repair protein O6-methylguanine-DNA methyltransferase are both required for its nuclear localization: the possible implications. EMBO J., 1996, 15(15), 4050-4060.
25. Coulter, R.; Blandino, M.; Tomlinson, J.M.; Pauly, G.T.; Krajewska, M.; Moschel, R.C.; Peterson, L.A.; Pegg, A.E.; Spratt, T.E. Differences in the rate of repair of O6-alkylguanines in different sequence contexts by O6-alkylguanine-DNA alkyltransferase. Chem. Res. Toxicol., 2007, 20(12), 1966-1971.
26. Fang, Q.; Noronha, A.M.; Murphy, S.P.; Wilds, C.J.; Tubbs, J.L.; Tainer, J.A.; Chowdhury, G.; Guengerich, F.P.; Pegg, A.E. Repair of O6-G-alkyl-O6-G interstrand cross-links by human O6-alkylguanine-DNA alkyltransferase. Biochemistry, 2008, 47(41), 10892-10903.
27. Pegg, A.E. Repair of O(6)-alkylguanine by alkyltransferases. Mutat. Res., 2000, 462(2-3), 83-100.
28. Pegg, A.E.; Dolan, M.E.; Moschel, R.C. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid Res. Mol. Biol., 1995, 51, 167-223.
29. Srivenugopal, K.S.; Yuan, X.H.; Friedman, H.S.; Ali-Osman, F. Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry, 1996, 35(4), 1328-1334.
30. Kaina, B.; Christmann, M. DNA repair in resistance to alkylating anticancer drugs. Int.J. Clin. Pharmacol. Ther., 2002, 40(8), 354-367.
31. Margison, G.P.; Povey, A.C.; Kaina, B.; Santibanez Koref, M.F. Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis, 2003, 24(4), 625-635.
32. Kaina, B.; Christmann, M.; Naumann, S.; Roos, W.P. MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair, 2007, 6(8), 1079-1099.
33. Mouawad, R.; Sebert, M.; Michels, J.; Bloch, J.; Spano, J.P.; Khayat, D. Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit. Rev. Oncol. Hematol., 2010, 74(1), 27-39.
34. Silber, J.R.; Blank, A.; Bobola, M.S.; Ghatan, S.; Kolstoe, D.D.; Berger, M.S. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin. Cancer Res., 1999, 5(4), 807-814.
35. Gerson, S.L. Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol., 2002, 20(9), 2388-2399.
36. Gerson, S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer, 2004, 4(4), 296-307.
37. Gerson, S.L.; Willson, J.K. O6-alkylguanine-DNA alkyltransferase. A target for the modulation of drug resistance. Hematol. Oncol. Clin. North Am., 1995, 9(2), 431-450.
38. Rolhion, C.; Penault-Llorca, F.; Kemeny, J.L.; Kwiatkowski, F.; Lemaire, J.J.; Chollet, P.; Finat-Duclos, F.; Verrelle, P. O(6)-methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation. Int. J. Cancer, 1999, 84(4), 416-420.
39. Bacolod, M.D.; Johnson, S.P.; Pegg, A.E.; Dolan, M.E.; Moschel, R.C.; Bullock, N.S.; Fang, Q.; Colvin, O.M.; Modrich, P.; Bigner, D.D.; Friedman, H.S. Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Mol. Cancer Ther., 2004, 3(9), 1127-1135.
40. Esteller, M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 629-656.
41. Esteller, M.; Herman, J.G. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene, 2004, 23(1), 1-8.
42. Middleton, M.R.; Margison, G.P. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol., 2003, 4(1), 37-44.
43. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S.N.; Hidalgo, O.F.; Vanaclocha, V.; Baylin, S.B.; Herman, J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med., 2000, 343(19), 1350-1354.
44. Sabharwal, A.; Middleton, M.R. Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. Curr. Opin. Pharmacol., 2006, 6(4), 355-363.
45. Blanc, J.L.; Wager, M.; Guilhot, J.; Kusy, S.; Bataille, B.; Chantereau, T.; Lapierre, F.; Larsen, C.J.; Karayan-Tapon, L. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J. Neurooncol., 2004, 68(3), 275-283.
46. Stupp, R.; Hegi, M.E.; van den Bent, M.J.; Mason, W.P.; Weller, M.; Mirimanoff, R.O.; Cairncross, J.G.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Changing paradigms-An update on the multidisciplinary management of malignant glioma. Oncologist, 2006, 11(2), 165-180.
47. Hegi, M.E.; Diserens, A.; Gorlia, T.; Hamou, M.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.; Mason, W.; Mariani, L.; Bromberg, J.E.C.; Hau, P.; Mirimanoff, R.O.; Cairncross, J.G.; Janzer, R.C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med., 2005, 352(10), 997-1003.
48. Hegi, M.E.; Diserens, A.-C.; Godard, S.; Dietrich, P.-Y.; Regli, L.; Ostermann, S.; Otten, P.; Van Melle, G.; de Tribolet, N.; Stupp, R. Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide. Clin. Cancer Res., 2004, 10(6), 1871-1874.
49. Hegi, M.E.; Liu, L.; Herman, J.G.; Stupp, R.; Wick, W.; Weller, M.; Mehta, M.P.; Gilbert, M.R. Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. J. Clin. Oncol., 2008, 26(25), 4189-4199.
50. Bignami, M.; Casorelli, I.; Karran, P. Mismatch repair and response to DNA-damaging antitumour therapies. Eur. J. Cancer, 2003, 39(15), 2142-2149.
51. Christmann, M.; Tomicic, M.T.; Roos, W.P.; Kaina, B. Mechanisms of human DNA repair: an update. Toxicology, 2003, 193(1-2), 3-34.
52. Umar, A.; Risinger, J.I.; Glaab, W.E.; Tindall, K.R.; Barrett, J.C.; Kunkel, T.A. Functional overlap in mismatch repair by human MSH3 and MSH6. Genetics, 1998, 148(4), 1637-1646.
53. Chai, S.M.; Zeps, N.; Shearwood, A.M.; Grieu, F.; Charles, A.; Harvey, J.; Goldblatt, J.; Joseph, D.; Iacopetta, B. Screening for defective DNA mismatch repair in stage II and III colorectal cancer patients. Clin. Gastroenterol. Hepatol., 2004, 2(11), 1017-1025.
54. Gologan, A.; Sepulveda, A.R. Microsatellite instability and DNA mismatch repair deficiency testing in hereditary and sporadic gastrointestinal cancers. Clin. Lab. Med., 2005, 25(1), 179-196.
55. Peltomaki, P. Role of DNA Mismatch Repair Defects in the Pathogenesis of Human Cancer. J. Clin. Oncol., 2003, 21(6), 1174-1179.
56. Fink, D.; Aebi, S.; Howell, S.B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res., 1998, 4(1), 1-6.
57. Grady, W.M.; Carethers, J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology, 2008, 135(4), 1079-1099.
58. Herman, J.G.; Umar, A.; Polyak, K.; Graff, J.R.; Ahuja, N.; Issa, J.P.; Markowitz, S.; Willson, J.K.; Hamilton, S.R.; Kinzler, K.W.; Kane, M.F.; Kolodner, R.D.; Vogelstein, B.; Kunkel, T.A. Baylin, S.B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 1998, 95(12), 6870-6875.
59. Grady, W.M.; Rajput, A.; Lutterbaugh, J.D.; Markowitz, S.D. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res., 2001, 61(3), 900-902.
60. Zhang, J.S.M.; Hummersone, M.; Madhusudan, S.; Laughton, CA.; Bradshaw, T.D. Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair Oncology, 2011, in press.
61. Karran, P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis, 2001, 22(12), 1931-1937.
62. Wood, R.D.; Mitchell, M.; Sgouros, J.; Lindahl, T. Human DNA repair genes. Science, 2001, 291(5507), 1284-1289.
63. Hickson, I.D., Ed. Base excision repair of DNA damage; Landes Bioscience and Chapman and Hall: Austin, Texas, 1997. ISBN 0412131617.
64. Lindahl, T.; Karran, P.; Wood, R.D. DNA excision repair pathways. Curr. Opin. Genet. Dev., 1997, 7(2), 158-169.
65. Dantzer, F.; Ame, J.C.; Schreiber, V.; Nakamura, J.; Menissier-de Murcia, J.; de Murcia, G. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair. Methods Enzymol., 2006, 409, 493-510.
66. Malanga, M.; Althaus, F.R. The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem. Cell Biol., 2005, 83(3), 354-364.
67. Aguilar-Quesada, R.; Munoz-Gamez, J.A.; Martin-Oliva, D.; Peralta-Leal, A.; Quiles-Perez, R.; Rodriguez-Vargas, J.M.; Ruiz de Almodovar, M.; Conde, C.; Ruiz-Extremera, A.; Oliver, F.J. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr. Med. Chem., 2007, 14(11), 1179-1187.
68. Lockett, K.L.; Snowhite, I.V.; Hu, J.J. Nucleotide-excision repair and prostate cancer risk. Cancer Lett., 2005, 220(2), 125-135.
69. Sobol, R.W.; Horton, J.K.; Kuhn, R.; Gu, H.; Singhal, R.K.; Prasad, R.; Rajewsky, K.; Wilson, S.H. Requirement of mammalian DNA polymerase-beta in base-excision repair. Nature, 1996, 379(6561), 183-186.
70. Curtin, N.J.; Wang, L.Z.; Yiakouvaki, A.; Kyle, S.; Arris, C.A.; Canan-Koch, S.; Webber, S.E.; Durkacz, B.W.; Calvert, H.A.; Hostomsky, Z.; Newell, D.R. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin. Cancer Res., 2004, 10(3), 881-889.
71. Ratnam, K.; Low, J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res., 2007, 13(5), 1383-1388.
72. Tentori, L.; Portarena, I.; Vernole, P.; Gold, B.; Graziani, G. Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes. Cancer Chemother. Pharmacol., 2002, 49(3), 217-224.
73. Tentori, L.; Graziani, G. Recent approaches to improve the antitumor efficacy of temozolomide. Curr. Med. Chem., 2009, 16(2), 245-257.
74. Alvino, E.; Castiglia, D.; Caporali, S.; Pepponi, R.; Caporaso, P.; Lacal, P.M.; Marra, G.; Fischer, F.; Zambruno, G.; Bonmassar, E.; Jiricny, J.; D'Atri, S. A single cycle of treatment with temozolomide, alone or combined with O-6-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: Role of O-6-methylguanine-DNA methyltransferase and the mismatch repair system. Int. J. Oncol., 2006, 29(4), 785-797.
75. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer, 2005, 5(4), 275-284.
76. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature, 2004, 432(7015), 396-401.
77. Persidis, A. Cancer multidrug resistance. Nat. Biotechnol., 1999, 17(1), 94-95.
78. Bradshaw, T.D.; Stone, E.L.; Trapani, V.; Leong, C.O.; Matthews, C.S.; te Poele, R.; Stevens, M.F. Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines. Breast Cancer Res. Treat., 2008, 110(1), 57-68.
79. Longley, D.B.; Johnston, P.G. Molecular mechanisms of drug resistance. J. Pathol., 2005, 205(2), 275-292.
80. Shi, X.; Liu, S.; Kleeff, J.; Friess, H.; Buchler, M.W. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosisregulating genes. Oncology, 2002, 62(4), 354-362.
81. Calatozzolo, C.; Gelati, M.; Ciusani, E.; Sciacca, F.L.; Pollo, B.; Cajola, L.; Marras, C.; Silvani, A.; Vitellaro-Zuccarello, L.; Croci, D.; Boiardi, A.; Salmaggi, A. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J. Neurooncol., 2005, 74(2), 113-121.
82. Schaich, M.; Kestel, L.; Pfirrmann, M.; Robel, K.; Illmer, T.; Kramer, M.; Dill, C.; Ehninger, G.; Schackert, G.; Krex, D. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann. Oncol., 2009, 20(1), 175-181.
83. Lefranc, F.; Rynkowski, M.; DeWitte, O.; Kiss, R. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv. Tech. Stand. Neurosurg., 2009, 34, 3-35.
84. Bobola, M.S.; Tseng, S.H.; Blank, A.; Berger, M.S.; Silber, J.R. Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin. Cancer Res., 1996, 2(4), 735-741.
85. Wiewrodt, D.; Nagel, G.; Dreimuller, N.; Hundsberger, T.; Perneczky, A.; Kaina, B. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Int. J. Cancer, 2008, 122(6), 1391-1399.
86. Kitange, G.J.; Carlson, B.L.; Schroeder, M.A.; Grogan, P.T.; Lamont, J.D.; Decker, P.A.; Wu, W.; James, C.D.; Sarkaria, J.N. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro. Oncol., 2009, 11(3), 281-291.
87. Zhang, J.; Stevens, M.F.; Laughton, C.A.; Madhusudan, S.; Bradshaw, T.D. Acquired Resistance to Temozolomide in Glioma Cell Lines: Molecular Mechanisms and Potential Translational Applications. Oncology, 2010, 78(2), 103-114.
88. Grombacher, T.; Mitra, S.; Kaina, B. Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis, 1996, 17(11), 2329-2336.
89. Eckert, A.; Kloor, M.; Giersch, A.; Ahmadi, R.; Herold-Mende, C.; Hampl, J.A.; Heppner, F.L.; Zoubaa, S.; Holinski-Feder, E.; Pietsch, T.; Wiestler, O.D.; von Knebel Doeberitz, M.; Roth, W.; Gebert, J. Microsatellite instability in pediatric and adult highgrade gliomas. Brain Pathol., 2007, 17(2), 146-150.
90. Cahill, D.P.; Levine, K.K.; Betensky, R.A.; Codd, P.J.; Romany, C.A.; Reavie, L.B.; Batchelor, T.T.; Futreal, P.A.; Stratton, M.R.; Curry, W.T.; Iafrate, A.J.; Louis, D.N. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin. Cancer Res., 2007, 13(7), 2038-2045.
91. Cahill, D.P.; Codd, P.J.; Batchelor, T.T.; Curry, W.T.; Louis, D.N. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. Clin. Neurosurg., 2008, 55, 165-171.
92. Friedman, H.S.; Johnson, S.P.; Dong, Q.; Schold, S.C.; Rasheed, B.K.; Bigner, S.H.; Ali-Osman, F.; Dolan, E.; Colvin, O.M.; Houghton, P.; Germain, G.; Drummond, J.T.; Keir, S.; Marcelli, S.; Bigner, D.D.; Modrich, P. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res., 1997, 57(14), 2933-2936.
93. Yip, S.; Miao, J.; Cahill, D.P.; Iafrate, A.J.; Aldape, K.; Nutt, C.L.; Louis, D.N. MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance. Clin. Cancer Res., 2009, 15(14), 4622-4629.
94. Casorelli, I.; Russo, M.T.; Bignami, M. Role of mismatch repair and MGMT in response to anticancer therapies. Anticancer Agents Med. Chem., 2008, 8(4), 368-380.
95. Trivedi, R.N.; Almeida, K.H.; Fornsaglio, J.L.; Schamus, S.; Sobol, R.W. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res., 2005, 65(14), 6394-6400.
96. Silber, J.R.; Bobola, M.S.; Blank, A.; Schoeler, K.D.; Haroldson, P.D.; Huynh, M.B.; Kolstoe, D.D. The Apurinic/Apyrimidinic Endonuclease Activity of Ape1/Ref-1 Contributes to Human Glioma Cell Resistance to Alkylating Agents and Is Elevated by Oxidative Stress. Clin. Cancer Res., 2002, 8(9), 3008-3018.
97. Bobola, M.S.; Finn, L.S.; Ellenbogen, R.G.; Geyer, J.R.; Berger, M.S.; Braga, J.M.; Meade, E.H.; Gross, M.E.; Silber, J.R. Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clin. Cancer Res., 2005, 11(20), 7405-7414.
98. Bobola, M.S.; Emond, M.J.; Blank, A.; Meade, E.H.; Kolstoe, D.D.; Berger, M.S.; Rostomily, R.C.; Silbergeld, D.L.; Spence, A.M.; Silber, J.R. Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy. Clin. Cancer Res., 2004, 10(23), 7875-7883.
99. Al-Attar, A.; Gossage, L.; Fareed, K.R.; Shehata, M.; Mohammed, M.; Zaitoun, A.M.; Soomro, I.; Lobo, D.N.; Abbotts, R.; Chan, S.; Madhusudan, S. Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br. J. Cancer, 2010, 102(4), 704-709.
100. Verbeek, B.; Southgate, T.D.; Gilham, D.E.; Margison, G.P. O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br. Med. Bull., 2008, 85, 17-33.
101. Dolan, M.E.; Pegg, A.E. O6-benzylguanine and its role in chemotherapy. Clin. Cancer Res., 1997, 3(6), 837-847.
102. Dolan, M.E.; Moschel, R.C.; Pegg, A.E. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl. Acad. Sci. USA. 1990, 87(14), 5368-5372.
103. Middleton, M.R.; Kelly, J.; Thatcher, N.; Donnelly, D.J.; McElhinney, R.S.; McMurry, T.B.; McCormick, J.E.; Margison, G.P. O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int. J. Cancer, 2000, 85(2), 248-252.
104. Middleton, M.R.; Thatcher, N.; McMurry, T.B.; McElhinney, R.S.; Donnelly, D.J.; Margison, G.P. Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model. Int. J. Cancer, 2002, 100(5), 615-617.
105. Ranson, M.; Middleton, M.R.; Bridgewater, J.; Lee, S.M.; Dawson, M.; Jowle, D.; Halbert, G.; Waller, S.; McGrath, H.; Gumbrell, L.; McElhinney, R.S.; Donnelly, D.; McMurry, T.B.; Margison, G.P. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNAalkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res., 2006, 12(5), 1577-1584.
106. Ranson, M.; Hersey, P.; Thompson, D.; Beith, J.; McArthur, G.A.; Haydon, A.; Davis, I.D.; Kefford, R.F.; Mortimer, P.; Harris, P.A.; Baka, S.; Seebaran, A.; Sabharwal, A.; Watson, A.J.; Margison, G.P.; Middleton, M.R. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J. Clin. Oncol., 2007, 25(18), 2540-2545.
107. Watson, A.J.; Middleton, M.R.; McGown, G.; Thorncroft, M.; Ranson, M.; Hersey, P.; McArthur, G.; Davis, I.D.; Thomson, D.; Beith, J.; Haydon, A.; Kefford, R.; Lorigan, P.; Mortimer, P.; Sabharwal, A.; Hayward, O.; Margison, G.P. O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Br. J. Cancer, 2009, 100(8), 1250-1256.
108. Watson, A.J.; Sabharwal, A.; Thorncroft, M.; McGown, G.; Kerr, R.; Bojanic, S.; Soonawalla, Z.; King, A.; Miller, A.; Waller, S.; Leung, H.; Margison, G.P. Middleton, M.R. Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib. Clin. Cancer Res., 2010, 16(2), 743-749.
109. Hansen, W.K.; Kelley, M.R. Review of mammalian DNA repair and translational implications. J. Pharmacol. Exp. Ther., 2000, 295(1), 1-9.
110. Woolford, L.B.; Southgate, T.D.; Margison, G.P.; Milsom, M.D.; Fairbairn, L.J. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine. J. Gene Med., 2006, 8(1), 29-34.
111. Zielske, S.P.; Gerson, S.L. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. Mol. Ther., 2002, 5(4), 381-387.
112. Tentori, L.; Leonetti, C.; Scarsella, M.; d'Amati, G.; Portarena, I.; Zupi, G.; Bonmassar, E.; Graziani, G. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002, 99(6), 2241-2244.
113. Drew, Y.; Plummer, R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist. Updat., 2009, 12(6), 153-156.
114. Plummer, E.R. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr. Opin. Pharmacol., 2006, 6(4), 364-368.
115. Palma, J.P.; Wang, Y.C.; Rodriguez, L.E.; Montgomery, D.; Ellis, P.A.; Bukofzer, G.; Niquette, A.; Liu, X.; Shi, Y.; Lasko, L.; Zhu, G.D.; Penning, T.D.; Giranda, V.L.; Rosenberg, S.H.; Frost, D.J.; Donawho, C.K. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin. Cancer Res., 2009, 15(23), 7277-7290.
116. Plummer, R.; Lorigan, P.; Evans, J.; Steven, N.; Middleton, M.; Wilson, R.; Snow, K.; Dewji, R.; Calvert, H. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J. Clin. Pharmacol., 2006, 456.
117. Fong, P.C.; Boss, D.S.; Yap, T.A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O'Connor, M.J.; Ashworth, A.; Carmichael, J.; Kaye, S.B.; Schellens, J.H.; de Bono, J.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med., 2009, 361(2), 123-134.
118. Sandhu, S.K.; Yap, T.A.; de Bono, J.S. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur. J. Cancer, 2010, 46(1), 9-20.
119. Tutt, A.; Robson, M.; Garber, J.E.; Domchek, S.M.; Audeh, M.W.; Weitzel, J.N.; Friedlander, M.; Arun, B.; Loman, N.; Schmutzler, R.K.; Wardley, A.; Mitchell, G.; Earl, H.; Wickens, M.; Carmichael, J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, 2010, 376(9737), 235-244.
120. Stebbing, J.; Ellis, P.; Tutt, A. PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers. Future Oncol., 2010, 6(4), 485-486.
121. Liu, X.; Han, E.K.; Anderson, M.; Shi, Y.; Semizarov, D.; Wang, G.; McGonigal, T.; Roberts, L.; Lasko, L.; Palma, J.; Zhu, G.D.; Penning, T.; Rosenberg, S.; Giranda, V.L.; Luo, Y.; Leverson, J.; Johnson, E.F.; Shoemaker, A.R. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol. Cancer Res., 2009, 7(10), 1686-1692.
122. Abbotts, R.; Madhusudan, S. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat. Rev., 2010, 36(5), 425-435.
123. Mendez, F.; Goldman, J.D.; Bases, R.E. Abasic sites in DNA of HeLa cells induced by lucanthone. Cancer Invest., 2002, 20(7-8), 983-991.
124. Fishel, M.L.; He, Y.; Smith, M.L.; Kelley, M.R. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin. Cancer Res., 2007, 13(1), 260-267.
125. Liu, L.L.; Nakatsuru, Y.; Gerson, S.L. Base excision repair as a therapeutic target in colon cancer. Clin. Cancer Res., 2002, 8(9), 2985-2991.
126. Taverna, P.; Liu, L.; Hwang, H.S.; Hanson, A.J.; Kinsella, T.J.; Gerson, S.L. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat. Res., 2001, 485(4), 269-281.